Fig. 4: miR199a-5p leads to hepatic insulin resistance via ATG14 in vivo.
From: miR199a-5p inhibits hepatic insulin sensitivity via suppression of ATG14-mediated autophagy
a–e Male C57BL/6J WT mice were infected with Ad-miR199a-5p (Ad-miR199a-5p) or the negative control (Ad-miR NC) and with Ad-ATG14 (Ad-ATG14) or the negative control (Ad-NC) via tail vein injection. a Day 9: measurement of hepatic ATG14 expression. b, c Days 6 and 5: examination of fed or fasting blood glucose and serum insulin levels. d HOMA-IR index. e Days 5 and 3: performance of GTTs and ITTs. The two-tailed Student's t-test was applied to determine the difference between the Ad-miR199a-5p group and the corresponding control group (*P < 0.05, **P < 0.01, ***P < 0.001) or between the Ad-miR199a-5p group with Ad-ATG14 and the Ad-miR199a-5p group without Ad-ATG14. (aP < 0.05, aaP < 0.01, aaaP < 0.001), n = 6 mice per group. f–j: Male C57BL/6J WT mice were infected with Ad-ATG14 or Ad-NC via tail vein injection. f Day 9: measurement of hepatic ATG14 expression. g, h Days 6 and 5: examination of fed or fasting blood glucose and serum insulin levels. i HOMA-IR index. j Days 5 and 3: performance of GTTs and ITTs. The two-tailed Student's t-test was applied to determine the difference between the Ad-ATG14 group and the corresponding control group (*P < 0.05, **P < 0.01), n = 8 mice per group
